Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of Euro...
Ausführliche Beschreibung
Autor*in: |
Anja Vogt [verfasserIn] Ursula Kassner [verfasserIn] Ulrike Hostalek [verfasserIn] Elisabeth Steinhagen-Thiessen [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2007 |
---|
Übergeordnetes Werk: |
In: Vascular Health and Risk Management - Dove Medical Press, 2009, (2007), Issue 4, Seite 467-479 |
---|---|
Übergeordnetes Werk: |
year:2007 ; number:Issue 4 ; pages:467-479 |
Links: |
---|
Katalog-ID: |
DOAJ022905170 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ022905170 | ||
003 | DE-627 | ||
005 | 20230307062033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2007 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ022905170 | ||
035 | |a (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC666-701 | |
100 | 0 | |a Anja Vogt |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
264 | 1 | |c 2007 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk | ||
653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
700 | 0 | |a Ursula Kassner |e verfasserin |4 aut | |
700 | 0 | |a Ulrike Hostalek |e verfasserin |4 aut | |
700 | 0 | |a Elisabeth Steinhagen-Thiessen |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Vascular Health and Risk Management |d Dove Medical Press, 2009 |g (2007), Issue 4, Seite 467-479 |w (DE-627)481905839 |w (DE-600)2180578-7 |x 11782048 |7 nnns |
773 | 1 | 8 | |g year:2007 |g number:Issue 4 |g pages:467-479 |
856 | 4 | 0 | |u https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 |z kostenfrei |
856 | 4 | 0 | |u http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1176-6344 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1178-2048 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2007 |e Issue 4 |h 467-479 |
author_variant |
a v av u k uk u h uh e s t est |
---|---|
matchkey_str |
article:11782048:2007----::rlnerlaeioiiaifrhmngmnodsiieiaudticui |
hierarchy_sort_str |
2007 |
callnumber-subject-code |
RC |
publishDate |
2007 |
allfields |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479 |
spelling |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479 |
allfields_unstemmed |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479 |
allfieldsGer |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479 |
allfieldsSound |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479 |
language |
English |
source |
In Vascular Health and Risk Management (2007), Issue 4, Seite 467-479 year:2007 number:Issue 4 pages:467-479 |
sourceStr |
In Vascular Health and Risk Management (2007), Issue 4, Seite 467-479 year:2007 number:Issue 4 pages:467-479 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Diseases of the circulatory (Cardiovascular) system |
isfreeaccess_bool |
true |
container_title |
Vascular Health and Risk Management |
authorswithroles_txt_mv |
Anja Vogt @@aut@@ Ursula Kassner @@aut@@ Ulrike Hostalek @@aut@@ Elisabeth Steinhagen-Thiessen @@aut@@ |
publishDateDaySort_date |
2007-01-01T00:00:00Z |
hierarchy_top_id |
481905839 |
id |
DOAJ022905170 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022905170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307062033.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022905170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anja Vogt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (&lt;1.02 mmol/L [40 mg/dL] in men or &lt;1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan&reg; (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan&reg; have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan&reg; in a usual-care setting. The most common side-effect of Niaspan&reg; is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1&ndash;2 years of treatment with Niaspan&reg; plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan&reg;-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan&reg; represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan&reg;, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursula Kassner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrike Hostalek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabeth Steinhagen-Thiessen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vascular Health and Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2007), Issue 4, Seite 467-479</subfield><subfield code="w">(DE-627)481905839</subfield><subfield code="w">(DE-600)2180578-7</subfield><subfield code="x">11782048</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2007</subfield><subfield code="g">number:Issue 4</subfield><subfield code="g">pages:467-479</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1176-6344</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2048</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2007</subfield><subfield code="e">Issue 4</subfield><subfield code="h">467-479</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Anja Vogt |
spellingShingle |
Anja Vogt misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
authorStr |
Anja Vogt |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)481905839 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC666-701 |
illustrated |
Not Illustrated |
issn |
11782048 |
topic_title |
RC666-701 Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
topic |
misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system |
topic_unstemmed |
misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system |
topic_browse |
misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Vascular Health and Risk Management |
hierarchy_parent_id |
481905839 |
hierarchy_top_title |
Vascular Health and Risk Management |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)481905839 (DE-600)2180578-7 |
title |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
ctrlnum |
(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 |
title_full |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
author_sort |
Anja Vogt |
journal |
Vascular Health and Risk Management |
journalStr |
Vascular Health and Risk Management |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2007 |
contenttype_str_mv |
txt |
container_start_page |
467 |
author_browse |
Anja Vogt Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen |
class |
RC666-701 |
format_se |
Elektronische Aufsätze |
author-letter |
Anja Vogt |
author2-role |
verfasserin |
title_sort |
prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the nautilus study |
callnumber |
RC666-701 |
title_auth |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
abstract |
Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk |
abstractGer |
Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk |
abstract_unstemmed |
Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
Issue 4 |
title_short |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
url |
https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 https://doaj.org/toc/1176-6344 https://doaj.org/toc/1178-2048 |
remote_bool |
true |
author2 |
Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen |
author2Str |
Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen |
ppnlink |
481905839 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
RC666-701 |
up_date |
2024-07-03T14:39:58.490Z |
_version_ |
1803569173361590272 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022905170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307062033.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022905170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anja Vogt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (&lt;1.02 mmol/L [40 mg/dL] in men or &lt;1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan&reg; (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan&reg; have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan&reg; in a usual-care setting. The most common side-effect of Niaspan&reg; is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1&ndash;2 years of treatment with Niaspan&reg; plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan&reg;-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan&reg; represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan&reg;, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursula Kassner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrike Hostalek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabeth Steinhagen-Thiessen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vascular Health and Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2007), Issue 4, Seite 467-479</subfield><subfield code="w">(DE-627)481905839</subfield><subfield code="w">(DE-600)2180578-7</subfield><subfield code="x">11782048</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2007</subfield><subfield code="g">number:Issue 4</subfield><subfield code="g">pages:467-479</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1176-6344</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2048</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2007</subfield><subfield code="e">Issue 4</subfield><subfield code="h">467-479</subfield></datafield></record></collection>
|
score |
7.4007425 |